Related Experiment Video
Updated: Jun 6, 2026

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
Serum Cytokine Profiles in Patients with Inflammatory Bowel Disease in Clinical Remission: A Cross-Sectional
Sara Jarmakiewicz-Czaja1,2, Pawel R Kiela3, Dominika Piątek4
1Faculty of Health Sciences and Psychology, Collegium Medicum, University of Rzeszów, Rzeszów, Poland.
Introduction:
Inflammatory bowel diseases (IBDs) are a group of idiopathic diseases that include Crohn's disease (CD) and ulcerative colitis (UC). According to the Global Burden of Diseases, Injuries, and Risk Factors Study, 6.8 million people lived with IBD in 2017. Monitoring cytokine levels can provide information about the effectiveness of therapy and help adjust treatment to achieve better clinical outcomes. This cross-sectional study aimed to assess whether serum cytokine profiles differ between patients receiving anti-TNF therapy and those not receiving biologic treatment in a cohort restricted to clinical remission, and to evaluate their potential clinical utility.
Methods:
The study included 132 IBD patients who were in remission of the disease and 29 control subjects. Cytokine levels (GM-CSF, INFγ, IL13, IL1β, IL4, IL23, IL6, TNFα) were measured and compared between patients receiving biologic therapy and those not receiving biologic treatment.
Results:
No significant differences were observed in the concentrations of the cytokines studied between the individual groups of patients receiving anti-TNF therapy and those receiving conventional therapy. Overall, cytokine profiles showed limited discriminatory value in patients in clinical remission.
Conclusion:
Regardless of the treatment method used (conventional vs. biologic therapy), no differences were observed in the profiles of pro-inflammatory and anti-inflammatory cytokines among patients in clinical remission. These results suggest that blood levels of TNF-α and other cytokines do not depend solely on anti-TNF therapy, indicating the need for longitudinal studies to assess their potential role in predicting relapse or loss of response to treatment.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease II: Ulcerative Colitis
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory Bowel Disease III: Crohn's Disease
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...

